Drug Overview
Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis. Prostate cancer cell growth is commonly driven by hormones, and as Zytiga inhibits the rate-limiting enzyme in androgen synthesis, it blocks testosterone production activity in the testes, adrenal glands, and prostate, while preserving adrenal sufficiency.
Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis. Prostate cancer cell growth is commonly driven by hormones, and as Zytiga inhibits the rate-limiting enzyme in androgen synthesis, it blocks testosterone production activity in the testes, adrenal glands, and prostate, while preserving adrenal sufficiency.
Table of Contents
Product ProfilesZytiga: Prostate cancer
List of Figures
Figure 1: Zytiga for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Zytiga for prostate cancer
Figure 3: Drug assessment summary of Zytiga for prostate cancer
Figure 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Zytiga drug profile
Table 2: Zytiga Phase III data in prostate cancer
Table 3: Zytiga Phase III trials in prostate cancer
Table 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
